Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

13.63 +0.04 (+0.26%)
Streaming Delayed Price Updated: 11:05 AM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Worldwide Adoption of Novavax Vaccines Makes It a Winner
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels. 
Via InvestorPlace
Takeda Named Global Top Employer for Fifth Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
More Serious Matters
Wall Street fell on new worries about inflation and a drop in retail sales levels. 
Via Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
Denali Therapeutics is under pressure after the FDA put its study on hold. 
Via Investor's Business Daily
Interest Rate Hikes And Stocks
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore. 
Via Talk Markets
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
From Takeda Pharmaceutical Company Limited
Via Business Wire
Post-Fed Thursday
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today. 
Via Talk Markets
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral... 
Via Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With... 
Via Benzinga
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to... 
Via FinancialNewsMedia
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd... 
Via Benzinga
3 Stocks That Can Make You Rich in Just a Few Years
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. 
Via InvestorPlace
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at... 
Via Benzinga
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
From Takeda Pharmaceutical Company Limited
Via Business Wire
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
Happy December
Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices. 
Via Talk Markets
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after... 
Via Benzinga
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.